The Russian cancer vaccine is ready for use, Izvestia reported, citing Veronika Skvortsova, head of the Federal Medical-Biological Agency.
Preclinical studies have confirmed the safety and efficacy of the drug. At the end of the summer, the FMBA sent documents to the Ministry of Health to obtain permission for clinical use.
As previously reported, from September 2025, the vaccine will be used to treat patients with primary melanoma, as well as those who have undergone certain stages of therapy. The drug was developed by the Gamaleya Research Center for Epidemiology and Microbiology.
Read materials on the topic:
Russian cancer vaccine successfully passed preclinical trials
Now on home
Герой России Гарнаев: никто из профессионалов о возобновлении производства на КАЗ всерьёз не говорит
Система отслеживает спутники на высотах до 50 000 км и ведёт за ними наблюдение
The armored vehicle is equipped with a KamAZ-740.35-400 diesel engine with a power of 400 hp.
Constant improvements in avionics, weapons and tactical capabilities will make the aircraft a flexible response to future challenges
The exterior of the KamAZ-54901 features fairings on the cab and chassis for fuel economy
Fighters are in demand both domestically and abroad
Tyazhpromexport and Venezuela Agree on Plant Revival
The company not only completed the state order, but also quickly mastered the production of AK-12K for special forces
Experts have developed a photogrammetric complex with a resolution of less than 1 cm
